Cooperation between secretory phospholipase A2 and TNF-receptor superfamily signaling: Implications for the inflammatory response in atherogenesis

Circulation Research

Volumn 91, Issue 8, 2002, Pages 681-688

  Fuentes, Lucía ^a   Hernández, Marita ^a   Fernández Avilés, Francisco Jesús ^a   Sánchez Crespo, Mariano ^a   Nieto, María Luisa ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Apoptosis; Atherosclerosis; Cytokines; Inflammation; Lipid mediators

Indexed keywords

ACUTE PHASE PROTEIN; ARACHIDONIC ACID; CD11B ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CYCLOOXYGENASE 2; FAS ANTIGEN; FAS LIGAND; LIPOCORTIN 5; PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; APOPTOSIS; ARTERY WALL; ARTICLE; ATHEROGENESIS; CELL COUNT; CELL DEATH; CELL NUCLEUS; CELL SURVIVAL; CELL TYPE; CHROMATIN CONDENSATION; CONTROLLED STUDY; ENZYME MECHANISM; HUMAN; HUMAN CELL; INFLAMMATION; LEUKEMIA CELL LINE; MEDIATOR RELEASE; MONOCYTE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION;

ANTIGENS, CD40; ANTIGENS, CD95; APOPTOSIS; ARACHIDONIC ACID; ARTERIOSCLEROSIS; CD40 LIGAND; CELL LINE; CELL MOVEMENT; COCULTURE TECHNIQUES; FAS LIGAND PROTEIN; HUMANS; INFLAMMATION; JURKAT CELLS; MACROPHAGE-1 ANTIGEN; MEMBRANE GLYCOPROTEINS; MONOCYTES; PHOSPHOLIPASES A; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037131329     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000038341.34243.64     Document Type: Article

References (47)

1. Hansson GK. Immune mechanism in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:1876-1890.
2. Mallet S, Barclay AN. A new superfamily of cell surface proteins related to the nerve growth factor receptor. Immunol Today. 1991;12:220-223.
3. Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol. 1994;6:407-413.
4. Dadgostar H, Zarnegar B, Hoffmann A, Qin XF, Truong U, Rao G, Baltimore D, Cheng G. Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci USA. 2002;99:1497-1502.
5. Chu P, Wierda WG, Kipps TJ. CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. Blood. 2000;95:3853-3858.
6. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY. Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA. 1997;94:1931-1936.
7. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092-1103.
8. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, Flavell RA. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313-1316.
9. 3 integrin-dependent mechanism. Nat Med. 2002;8:247-252.
10. 2 expression in human aortic tissue in dependence on the degree of atherosclerosis. Atherosclerosis. 1999;144:73-78.
11. 2 in normal and atherosclerotic arteries: Activity of the isolated enzyme on low-density lipoproteins. Arterioscler Thromb Vasc Biol. 1997;17:300-309.
12. 2. Arterioscler Thromb Vasc Biol. 1999;19:1284-1290.
13. 2 in human arterial smooth muscle cells: Involvement of cell differentiation STAT-3 activation, and modulation by other cytokines. J Biol Chem. 2000;275:22895-22904.
14. 2 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 2000;20:1276-1282.
15. Fonteh AN, Samet JM, Reed W, Chilton FH. Mechanisms that account for the selective release of arachidonic acid from intact cells by secretory phospholipase A2. Biochim Biophys Acta. 1998;1393:256-266.
16. 2 elicits proinflammatory changes and upregulates the surface expression of fas ligand in monocytic cells: Potential relevance for atherogenesis. Circ Res. 2002;90:38-45.
17. 2 in murine bone marrow-derived mast cells. J Immunol. 2000;165:2773-2782.
18. 2 in the human astrocytoma cell line 1321N1. J Biol Chem. 1998;273:606-612.
19. 2: A role for cell surface glycosaminoglycans. Biochem Pharmacol. 2002;63:65-72.
20. 2: Induce cytokine release from blood and synovial fluid monocytes. Eur J Immunol. 2002;32:67-76.
21. 2 from plasma of patients with septic shock is associated with high density lipoproteins and C3 anaphylatoxin: Some implications for its functional role. Biochem J. 1995;306:167-175.
22. Alonso A, Bayón Y, Renedo M, Sánchez Crespo M. Stimulation of FcτR receptors induces monocyte chemoattractant protein-1 (MCP-1) in the human monocytic cell line THP-1 by a mechanism involving IκB-α degradation and formation of p50/p65 NF-κB/Rel complexes. Int Immunol, 2000;12:547-554.
23. Weinrauch Y, Abad C, Liang NS, Lowry SF, Weiss J. Mobilization of potent plasma bactericidal activity during systemic bacterial challenge: Role of group IIA phospholipase A2. J Clin Invest. 1998;102:633-638.
24. Afford SC, Rhandawa S, Eliopoulos AG, Hubscher SG, Young LS, Adams DH. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface FasL expression and amplifies Fas mediated hepatocyte death during allograft rejection. J Exp Med. 1999;189:441-446.
25. Shibaki A, Katz SI. Activation through CD40 ligation induces functional Fas ligand expression by Langerhans cells. 1. Eur J Immunol. 2001;31:3006-3015.
26. Krzesz R, Wagner AH, Cattaruzza M, Hecker M. Cytokine-inducible CD40 gene expression in vascular smooth muscle cells is mediated by nuclear factor KB and signal transducer and activation of transcription-1. FEBS Lett. 1999;453:191-196.
27. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;6:396-399.
28. Schonbeck U, Mach F, Bonnefoy JY, Loppnow H, Flad HD, Libby P. Ligation of CD40 activates interleukin 1β-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1β. J Biol Chem. 1997;272:19569-19574.
29. Mach F, Schonbeck U, Fabunmi RP. Murphy C, Atkinson E, Bonnefoy JY, Graber P, Libby P. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: Implications for tubule formation. Am J Pathol. 1999:154:229-238.
30. Karmann K. Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci U S A. 1995;92:4342-4346.
31. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394:200-203.
32. Schonbeck U, Sukhova GK, Shimizu K, Mach F, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA. 2000;97:7458-7463.
33. Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA. 2000;97:7464-7469.
34. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes: Regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med. 1993;178:669-674.
35. Young LS. Dawson CW, Brown KW, Rickinson AB. Identification of a human epithelial cell surface protein sharing an epitope with C3d/Epstein-Barr virus receptor molecule of B lymphocytes. Int J Cancer. 1989;43:786-794.
36. Karmman K, Hughes CCW, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells-inducibility by cytokines and funtional regulation of adhesion molecule expression. Proc Natl Acad Sci USA. 1995;92:4342-4346.
37. 2 in vascular disease. Cir Res. 2001;89:298-304.
38. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest. 1999;103:1487-1488.
39. Harats D, Shaish A, George J, Mulkins M, Kurihara H, Levkovitz H, Sigal E. Overexpression of 15-1ipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2000:20:2100-2105.
40. Cyrus T, Pratico D, Zhao L, Witztum JL, Rader DJ, Rokach J, FitzGerald GA, Funk CD. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice. Circulation. 2001;103:2277-2282.
41. George J, Afek A, Shaish A, Levkovitz H, Bloom N, Cyrus T, Zhao L, Funk CD, Sigal E, Harats D. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation. 2001;104:1646-1650.
42. Aiello RJ, Bourassa P-A, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol. 2002;22:443-449.
43. 2 production in human lung fibroblasts. J Immunol. 1998;160:1053-1057.
44. Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP, Smith TJ. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression: Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem. 1998;273:29615-29625.
45. Thienel U, Loike J, Yellin MJ. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell Immunol, 1999;198:87-95.
46. Afford SC, Ahmed-Choudhury J, Randhawa S, Russell C, Youster J, Crosby HA, Eliopoulos A, Hubscher SG, Young LS, Adams DH. CD40 activation-induced, Fas-dependent apoptosis and NF-κB/AP-1 signaling in human intrahepatic biliary epithelial cells. FASEB J. 2001;15:2345-2354.
47. Afford SC, Randhawa S, Eliopoulos AG, Hubscher SG, Young LS, Adams DH. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. J Exp Med. 1999;189:441-446.